GlobalData Plc
Acquisition Updates
Healthcare Division: Acquisition of Deallus
GlobalData Plc (‘GlobalData’ or the ‘Group’), a leading data, analytics, and insights platform, today announces further progress in its M&A strategy.
The Group announces that it has completed the acquisition of Deallus, a market-leading competitive intelligence solutions provider focused on the global life sciences sector.
During its 20 years in business, Deallus has built deep sector expertise through supporting clients in key therapy areas, including Oncology, Neuroscience, Vaccines, Rare Diseases, Cell & Gene, and Immunology. The combination creates the opportunity for the Group to build deeper, more embedded relationships with major brands within the pharmaceutical sector and creates the potential for GlobalData to deliver more value to our clients.
The transaction was funded by the Group’s new recently announced debt facilities and completed on 31 December 2024. This represents the fourth acquisition completed in H2 2024, in addition to the acquisitions of Business Trade Media International, LinkUp and Celent, which also completed on 31 December 2024 following the satisfaction of certain closing conditions.
The Group will issue an update on its trading and FY24 results on 14 January 2025 and will provide further detail on the positive impact of its recent M&A activity.
Mike Danson, CEO of GlobalData PLC, commented: “This acquisition further enhances our capabilities in delivering life sciences solutions, allowing us to deliver even more comprehensive insights and services to our clients. Deallus’s deep sector expertise and client-first mindset perfectly align with our mission to empower decision-makers in navigating the complexities of the healthcare landscape. Together, we are poised to drive remarkable growth and deliver exceptional value to our stakeholders.”